About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 72207 record(s)
Req # A-2019-001790
The Human Drug Advisory Panel report of the Patented Medicines Prices Review Board (PMPRB) for erenumab (Aimovig). The timeline is from January 2018 until January 2020.Organization: Health Canada
February 2020
Req # A-2019-001793
Any Patented Medicines Prices Review Board (PMPRB) documentation related to erenumab (Aimovig) scientific review and also erenumab (Aimovig) pricing review from January 1, 2018 to January 31, 2020.Organization: Health Canada
February 2020
Req # A-2019-001797
Introductory Price Review for erenumab (Aimovig) by Patented Medicines Prices Review Board (PMPRB). The timeline range is from January 2018 until January 2020.Organization: Health Canada
February 2020
Req # A-2019-001879
All data held by Health Canada on lead concentrations in the drinking water of schools and daycares in First Nations communities from January 1, 2013 to February 14, 2020.Organization: Health Canada
February 2020
Req # A-2019-000635
Adverse Reaction Report (AER) for METRONIDAZOLE. Report numbers: E2B_02045004, E2B_02226857, E2B_01837100, E2B_01850701, E2B_02045004, E2B_02055143, 000716193, 000718447, E2B_02020476, E2B_02024833, 000720176, 000720744, E2B_02200695, E2B_02202620,…Organization: Health Canada
February 2020
Req # A-2019-001880
All records related to how allocations through the First Nations Infrastructure fund are calculated with respect to funding for fire safety and infrastructure operations from January 1, 2010 to February 14, 2020.Organization: Health Canada
February 2020
Req # A-2019-001961
Internal correspondence (director-level and above), briefing materials related to M-174 (National Suicide Prevention Action Plan) from April 12, 2018 to February 26, 2020.Organization: Health Canada
February 2020
Req # A-2018-001847
Adverse Reaction Report (AER). Report numbers: E2B_1459859, E2B_1868158, E2B_1608785, E2B_1749489, E2B_1756985, E2B_1488673, E2B_1465304, E2B_1569944, E2B_1799808, E2B_2022012, E2B_1553204, E2B_1831642, E2B_1959239.Organization: Health Canada
February 2020
Req # A-2019-000101
Adverse Reaction Report (AER) for PANTOPRAZOLE MAGNESIUM. Report numbers: 718285, 720360, E2B_02142492, E2B_02151677, E2B_02164185, E2B_02186484, E2B_02211397, E2B_02252769.Organization: Health Canada
February 2020
Req # A-2019-000385
Adverse Reaction Report (AER) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_01681346, E2B_01747187, E2B_01774476, E2B_01726431, E2B_01777645, E2B_01671894, E2B_01747195, E2B_01659269, E2B_01657868, E2B_01661946, E2B_01657837, E2B_01745892,…Organization: Health Canada
February 2020